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Introduction 
Trastuzumab emtansine (T-DM1; RO5304020) is a novel human epidermal growth factor 
receptor 2 (HER2)-directed antibody-drug conjugate. T-DM1 comprises the monoclonal 
antibody trastuzumab bound to potent anti-microtubule agent DM1, a maytansine 
derivative, via a stable linker. T-DM1 demonstrated robust clinical efficacy with less 
toxicity in the EMILIA trial [1, 2], a phase III study of T-DM1 versus lapatinib plus 
capecitabine in patients with previously treated HER2-positive advanced breast cancer. 
T-DM1 significantly improved both median progression-free survival (PFS; hazard ratio 
[HR], 0.65; 95% confidence interval [CI], 0.55–0.77; p < 0.001; 9.6 versus 6.4 months) 
and overall survival (OS; HR, 0.68; 95% CI, 0.55–0.85; p < 0.001; 30.9 versus 25.1 
months) [1]. Results from the TH3RESA trial, another phase III study of T-DM1 versus 
a treatment of the physician’s choice in patients with heavily treated HER2-positive 
advanced breast cancer, confirmed those of the EMILIA trial, with significant 
prolongation of both median PFS (HR, 0.53; 95% CI, 0.42–0.66; p < 0.0001; 6.2 versus 
3.3 months) [3] and OS (HR, 0.68; 95% CI, 0.54–0.85; p = 0.0007; 22.7 versus 15.8 
months) [4]. 
Pertuzumab (RO4368451) is a novel recombinant, humanized immunoglobulin (Ig) 
G1κ monoclonal antibody against HER2. The combination of pertuzumab, trastuzumab, 
and docetaxel tremendously prolonged both median PFS (HR, 0.62, 95% CI, 0.51–0.75; 
p < 0.001; 18.5 versus 12.4 months) and OS (HR, 0.68, 95% CI, 0.56–0.84; p < 0.001; 
56.5 versus 40.8 months) in patients with previously untreated HER2-positive metastatic 
breast cancer in the phase III CLEOPATRA trial [5-7]. 
The combination of T-DM1 and pertuzumab has been tested in a preclinical study [8] 
and a phase Ib/IIa study [9], suggesting synergistic antitumor activity. These results 
provided the rationale for conducting a global phase III MARIANNE trial [10, 11]. In the 
MARIANNE trial, T-DM1 or T-DM1 plus pertuzumab was compared with trastuzumab 
plus a taxane in patients with previously untreated HER2-positive advanced breast cancer. 
T-DM1 alone or in combination with pertuzumab did not significantly differ in efficacy 
to that of trastuzumab plus a taxane. The median PFS was 15.2 months with T-DM1 plus 
pertuzumab (HR, 0.87; 95% CI, 0.69–1.08; p = 0.14) and 14.1 months with T-DM1 (HR, 
0.91; 95% CI, 0.73–1.13, p = 0.31), whereas the median PFS was 13.7 months with 
trastuzumab plus a taxane. The median OS rates were 51.8, 53.7, and 50.9 months for T-
DM1 plus pertuzumab, T-DM1, and trastuzumab plus a taxane, respectively. 
This phase Ib study was conducted to assess the safety, pharmacokinetics (PKs), and 
preliminary efficacy, and to confirm the recommended dose of T-DM1 in combination 
with pertuzumab in Japanese patients with HER2-positive metastatic breast cancer before 
participating in the MARIANNE trial from Japan. 
 
Patients and Methods 
Study design 
This was a multicenter, non-randomized, open-label, phase Ib study of the combination 
of T-DM1 plus pertuzumab in Japanese patients with HER2-positive metastatic breast 
cancer. The primary objective was to assess the safety and PKs of T-DM1 in combination 
with pertuzumab in Japanese patients with HER2-positive metastatic breast cancer. The 
secondary objective was to assess antitumor activity. 
The study protocol was approved by the Institutional Review Board at each site, and 
all patients provided written informed consent for study participation. The study was 
conducted in accordance with the Declaration of Helsinki, the Pharmaceutical Affairs 
Laws, and the International Conference on Harmonisation Good Clinical Practice (ICH-
GCP). This study was registered at the Japan Pharmaceutical Information Center-Clinical 
Trials Information (JapicCTI-101234). 
 
Patients 
Women ≥ 20 years old with histologically or cytologically diagnosed inoperable advanced 
or recurrent HER2-positive breast cancer (immunohistochemistry [IHC] 3+ or 
fluorescence in situ hybridization [FISH] positive by central testing) were eligible. 
Disease progression was required during or after treatment with trastuzumab (including 
adjuvant therapy) and prior systemic chemotherapy for the advanced or recurrent breast 
cancer, with no other preferred treatment. Other inclusion criteria included an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate organ 
and bone marrow function, defined as an absolute neutrophil count of ≥ 1500/mm3, 
platelet count ≥ 100000/mm3, hemoglobin ≥ 9.0 g/dL, total bilirubin (T-Bil) ≤ 1.5 mg/dL, 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × the upper 
limit of normal (ULN), serum albumin ≥ 2.5 g/dL, serum creatinine ≤ 1.5 mg/dL or 
creatinine clearance ≥ 50 ml/min, and left ventricular ejection fraction (LVEF) ≥ 50% as 
measured by echocardiography or a multiple-gated acquisition (MUGA) scan. 
Key exclusion criteria included clinically significant cardiac disease, defined as New 
York Heart Association (NYHA) II to IV heart failure; National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) grade ≥ 3 cardiac disorders, and 
a history of unstable angina, congestive heart failure, myocardial infarction, and 
ventricular arrhythmia requiring medical treatment within 6 months; administration of a 
cumulative doxorubicin dose of > 500 mg/m2 or equivalent (e.g. in the case of epirubicin, 
> 720 mg/m2); a history of grade ≥ 3 hypersensitivity to trastuzumab; and symptomatic 
brain metastasis. Patients who previously received T-DM1 or pertuzumab were excluded. 
 
Study treatment 
T-DM1 was administered at a dose of 3.6 mg/kg with full-dose pertuzumab (a loading 
dose of 840 mg and then 420 mg) intravenously every 3 weeks. T-DM1 was given after 
completion of the pertuzumab infusion over 90 minutes in Cycle 1, and if well-tolerated, 
over 30 minutes in subsequent cycles. Pertuzumab was given over 60 minutes in Cycle 1 
and 2, and if well-tolerated, over 30 minutes in subsequent cycles. Treatment was 
continued until objective disease progression or unacceptable toxicity was observed. 
 
Assessments 
Criteria for dose-limiting toxicity 
Dose-limiting toxicities (DLTs) were defined as any of the following treatment-related 
adverse events (AEs) occurring during Cycle 1: thrombocytopenia (grade ≥ 4) lasting for 
> 24 hours; anemia (grade ≥ 4); neutropenia (grade ≥ 4) lasting for > 4 days or 
accompanied by a fever of ≥ 38 °C; increased T-Bil, AST, ALT, or blood alkaline 
phosphatase (ALP) (grade ≥ 3) lasting for > 72 hours; non-hematologic toxicity (grade ≥ 
3) with the exception of controllable diarrhea, nausea, vomiting, and/or infusion-related 
reactions; AEs that required delaying the initiation of Cycle 2 by 21 days; or AEs judged 
to be intolerable by the investigator. Severity of the AEs was assessed in accordance with 
NCI-CTCAE version 4.0. To establish tolerability assessment criteria, we determined that 
the combination of T-DM1 and pertuzumab would be declared tolerable if ≤ 2 of the 6 
patients developed DLTs. 
 
Safety 
Safety assessments included AE reporting, physical examination, vital signs (blood 
pressure, pulse rate, and body temperature), laboratory testing (hematology, blood 
chemistry, coagulation profiles, and urinalysis), 12-lead electrocardiogram, and 
echocardiogram or MUGA scan. The echocardiogram or MUGA scan was measured 
every 2 cycles for the first 24 weeks, then every 4 cycles. 
 
PK sampling 
PK samples for T-DM1 and total trastuzumab in serum, as well as DM1 in plasma were 
collected pre-dose, 30 min, 3, 24, 48, and 96 h after the end of the infusion, as well as on 
Days 8 and 15 of Cycle 1; pre-dose, 30 min, 3 h, and on Day 8 of Cycle 3; pre-dose and 
at 30 min of Cycles 2, 4, 5, and 6; and at study completion. PK samples for pertuzumab 
were collected pre-dose, 30 min after the end of the pertuzumab infusion, and 30 min 
after the end of the T-DM1 infusion on Days 2, 5, 8, and 15 of Cycle 1; pre-dose and 30 
min after T-DM1 on Day 8 of Cycle 3; pre-dose and 30 min after T-DM1 for Cycles 2, 4, 
5, and 6; and at study completion. 
Serum concentrations of T-DM1, total trastuzumab and pertuzumab, anti-T-DM1 
antibodies, and anti-pertuzumab antibodies were analyzed using a validated enzyme-
linked immunosorbent assay from Pharmaceutical Product Development Inc. (Richmond, 
VA, USA). Concentrations of free DM1 in plasma were determined using a validated 
liquid chromatography and tandem mass spectrometry method from QPS Netherlands 
B.V. (Groningen, The Netherlands). The PK parameters of each patient, including
maximum serum concentration (Cmax), area under the time–concentration curve (AUC), 
terminal half-life (t1/2), clearance, and the apparent volume of distribution at steady state 
(Vss) were determined by noncompartmental analysis of concentration data for serum T-
DM1, serum total trastuzumab, and serum pertuzumab from Cycle 1, including data from 
immediately before Cycle 2 dosing; similar analyses of plasma free DM1 concentrations 
were performed. Summary statistics were calculated for concentrations of serum T-DM1, 
serum total trastuzumab, plasma free DM1, serum pertuzumab, and for PK parameters of 
T-DM1, total trastuzumab, free DM1, and pertuzumab. 
Samples for anti-T-DM1 antibodies and anti-pertuzumab antibodies were collected 
before pertuzumab infusion on Day 1 from Cycles 1 to 6 and at the follow-up visit. Assays 
for anti-T-DM1 antibodies and anti-pertuzumab antibodies, as well as drug concentration 
were performed centrally. 
SAS software (version 9.2, SAS Institute, Inc., NC, USA) was used for statistical 
analyses. 
 
Antitumor activity 
Tumor assessments using computed tomography (CT) or magnetic resonance imaging 
(MRI) scans of the chest, abdomen, and pelvis were performed every 6 weeks for the first 
4 assessments, then every 12 weeks. Tumor response was assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. 
 
Analysis populations and statistical analyses 
The intent-to-treat (ITT) and safety evaluable population included all patients who 
received one or more doses of the study treatment. The DLTs evaluable population was 
defined as patients from the ITT population who did not meet the unevaluable criteria for 
DLTs, including patients who discontinued study treatment for reasons other than 
treatment-related AEs during Cycle 1; patients with insufficient safety assessment during 
Cycle 1; or patients with insufficient study drug administration during Cycle 1 for reasons 
other than AEs. The PK evaluable population included patients who received one or more 
doses of T-DM1 and whose PK parameters were measured. 
The sample size was set to 6 patients to confirm tolerability, based on the Japanese 
Guidelines for Clinical Evaluation Methods of Anti-cancer Drugs and Guidelines for 
Exploratory Clinical Trials of Combination Anti-cancer Chemotherapy. Statistical 
analyses were descriptive. 
Results 
Six patients were enrolled from 4 institutes in Japan between August 2010 and October 
2010. All patients received study treatment, thus the ITT and safety evaluable population 
included all 6 patients. One patient was not evaluable for DLTs because administration of 
study treatment of Cycle 2 was initiated before meeting the administration continuation 
criteria. All 6 patients were evaluable for antitumor efficacy according to the RECIST 
criteria. 
Baseline characteristics for the six patients are shown in Table 1. Median patient age 
was 57.5 (range 46–68) years, most patients (83%) had an ECOG performance status of 
0. All patients had HER2 IHC 3+/FISH-positive breast cancer. Four patients (67%) had 
estrogen receptor (ER)-negative and progesterone receptor (PgR)-negative breast cancer, 
and 2 patients (33%) had ER-positive/PgR-negative breast cancer. 
 
Safety 
The median duration of treatment was eleven (range 1–32) cycles. All patients 
experienced ≥ 1 treatment-emergent AEs (TEAEs) of any grade. The incidence of TEAEs 
is listed in Table 2. The most common TEAEs observed in three or more patients were 
diarrhea (n = 4), AST increased, nausea, chills, pyrexia, rash, headache, dysgeusia, 
muscle spasms, and rhinorrhea (n = 3). Grade 3 or greater TEAEs were observed in three 
patients, including grade 3 AST increased, grade 3 LVEF decreased and grade 3 
neutrophil counts decreased (n = 1). A DLT was observed in one patient (grade 3 LVEF 
decreased); the patient had a moderate amount of pericardial effusion before initiating 
study treatment, and LVEF decreased from 51% at baseline to 26% on Day 15 of Cycle 
1. The patient discontinued study treatment, and LVEF recovered to 60% on Day 45. 
Since DLT was observed in only one out of the 5 DLT-evaluable patients, the data 
monitoring committee determined the combination of T-DM1 and pertuzumab to be 
tolerable in Japanese patients. 
Serious AEs (SAEs) were observed in two patients, including a grade 2 hemorrhagic 
gastric ulcer and grade 2 epistaxis. No AEs leading to death were observed. AEs leading 
to treatment discontinuation were observed in 4 patients and included epistaxis, serum 
bilirubin increased, LVEF decreased and AST increased (n = 1). AEs leading to dose 
reduction or treatment interruption were not observed, whereas AEs leading to treatment 
delay occurred in 4 patients and included AST increased, and platelet count decreased (n 
= 2), as well as ALT increased, blood ALP increased, epistaxis, hemoglobin decreased, 
serum bilirubin increased, hemorrhagic gastric ulcer, neutrophil count decreased and 
anemia (n = 1). 
 
Pharmacokinetics 
PK samples were obtained from all 6 enrolled patients. PK parameters for serum T-DM1, 
serum total trastuzumab, plasma free DM1, and serum pertuzumab are summarized in 
Table 3. Serum concentrations of T-DM1, total trastuzumab, and pertuzumab quickly 
reached steady state when administered repeatedly at three-week intervals; accumulation 
was insignificant. 
The PKs for serum T-DM1, serum total trastuzumab, and plasma free DM1 when T-
DM1 was administered in combination with pertuzumab were compared with the results 
from the Japanese phase I study (JO22591) [12] in which T-DM1 was investigated as a 
single-agent (Figure 1 and 2). PK parameters for serum T-DM1, serum total trastuzumab, 
and plasma free DM1 were in a similar range for both studies. The PKs for serum 
pertuzumab when administered in combination with T-DM1 were also compared with the 
results from the Japanese phase I study (JO17076) [13], in which pertuzumab as a single-
agent was investigated, and the CLEOPATRA trial, in which pertuzumab, as well as 
trastuzumab plus a taxane were investigated (Figure 3). PK parameters for serum 
pertuzumab were similar regardless of whether pertuzumab was administered alone or in 
combination with T-DM1 or with trastuzumab plus a taxane. 
All patients were tested for the presence of anti-T-DM1 and anti-pertuzumab 
antibodies. Two patients developed anti-T-DM1 antibodies and one patient developed 
anti-pertuzumab antibodies. One patient who was positive for both antibodies had earlier 
clearance of serum T-DM1, trastuzumab, and pertuzumab than that of the other patients; 
however, there were no obvious differences in plasma concentration of free DM1.  
 
Efficacy 
All 6 patients were evaluable for tumor response according to RECIST version 1.0. The 
best overall responses included a partial response (PR) in 3 patients (50%) and stable 
disease (SD) in 2 patients (33%); the response in 1 patient was not evaluable (NE). For 
the 3 patients who experienced a PR, the median duration of response was 259 (range 38–
554) days. 
The best overall responses of the patients who developed anti-T-DM1 antibodies, or anti-
T-DM1 and anti-pertuzumab antibodies was SD and PR, respectively. 
 
Discussion 
This was the first clinical trial examining T-DM1 and pertuzumab as a combination 
therapy in Japanese patients with HER2-positive metastatic breast cancer who previously 
received trastuzumab and a chemotherapy-containing treatment. T-DM1 administered in 
combination with pertuzumab was generally well tolerated. A DLT was found in one 
patient (grade 3 LVEF decreased); however, it resolved within 30 days. The results of this 
study satisfied the tolerability assessment criteria, and the combination of T-DM1 plus 
pertuzumab was concluded to be tolerable in Japanese patients. The PK parameters of T-
DM1 and pertuzumab were not affected by co-administration of the drugs. The effects of 
anti-drug antibodies on the efficacy and safety of T-DM1 and pertuzumab were unclear. 
Most patients had a durable response, with 3 PRs, despite having been previously treated 
with trastuzumab and chemotherapy-containing therapies for their metastatic disease, 
none of which showed progressive disease (PD). 
This phase Ib study was conducted mainly to assess the safety and pharmacokinetics 
of T-DM1 in combination with pertuzumab in Japanese patients with HER2-positive 
metastatic breast cancer before participating in the MARIANNE trial from Japan. The 
Japanese regulatory authority issued the Administrative Notice to the effect that 
tolerability data of investigational drugs in the Japanese population should be ensured 
including about conducting phase I trials in the Japanese population before participating 
in the global trial [14]. The combination of T-DM1 plus pertuzumab did not appear to 
substantially increase toxicity in our study, as reported in previous studies [9-11]. 
Nevertheless, results of the MARIANNE trial showed no additional benefit from adding 
pertuzumab to T-DM1 treatment [10]; therefore, the combination of T-DM1 with 
pertuzumab is not standard of care for patients with HER2-positive advanced breast 
cancer. 
The combination of T-DM1 with pertuzumab was also investigated in patients with 
HER2-positive early breast cancer. The phase III KRISTINE trial (NCT02131064) 
compared neoadjuvant T-DM1 plus pertuzumab with docetaxel plus carboplatin plus 
trastuzumab plus pertuzumab (TCH+P). The primary endpoint of KRISTINE trial was 
pathologic complete response (pCR). TCH+P yielded a significantly higher pCR rate 
(55.7%) than that of T-DM1 plus pertuzumab (44.4%) [15]. However, T-DM1 plus 
pertuzumab was associated with a better safety profile, a longer maintenance of patient-
reported health-related quality of life, and physical functioning. Another phase III study 
(KAITLIN; NCT01966471) comparing adjuvant anthracyclines followed by T-DM1 plus 
pertuzumab with anthracyclines followed by trastuzumab plus pertuzumab plus a taxane 
is ongoing. 
Considering the favorable safety profile of the combination of T-DM1 with 
pertuzumab, there is the possibility that the combination may be a preferable option for 
frail patients including elderly or patients with poor performance status who cannot 
tolerate toxicity attributable to cytotoxic agents. A confirmatory clinical trial targeting 
“unfit” patients will be needed. Furthermore, translational research for biomarkers may 
help to identify patients who can benefit most from the combination therapy of T-DM1 
and pertuzumab. 
In conclusion, the combination therapy of T-DM1 plus pertuzumab was tolerable for 
Japanese patients with HER2-positive metastatic breast cancer, suggesting the 
combination of T-DM1 with pertuzumab is useful; these results support participation in 
the MARIANNE study from Japan.  
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Table 1  Baseline Characteristics 
 N=6 
Madian age, years (range) 57.5 (46-68) 
ECOG PS, n 
0 
1 
 
5 
1 
HER2 status (IHC/FISH), n 
3+ / + 
2+ / + 
 
6 
0 
Hormone receptor (ER/PgR), n 
- / - 
+ / - 
 
4 
2 
HER2 targeted therapy as a component of neoadjuvant or adjuvant therapy 
Yes 
No 
 
6 
0 
HER2 targeted therapy for MBC 
Yes 
No 
 
6 
0 
Regimens for MBC, n (%) 
Trastuzumab 
Taxane 
Vinorelbine 
Lapatinib 
 
 6 (100.0) 
5 (83.3) 
3 (50.0) 
1 (16.7) 
Median number of prior regimens for MBC (range) 2.5 (1-5) 
Median number of prior trastuzumab-containing therapies for MBC (range) 2.5 (1-4) 
  
Table 2 Treatment-emergent adverse events (TEAEs) 
Grade 1 TEAEs that occurred in one case are excluded. 
* Dose-limiting toxicity
AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase 
Adverse event Any Grade 1 Grade 2 Grade 3 Grade 4 
Diarrhea 4 4 0 0 0 
AST increased 3 1 1 1 0 
Nausea 3 2 1 0 0 
Chills 3 3 0 0 0 
Pyrexia 3 3 0 0 0 
Rash 3 3 0 0 0 
Headache 3 3 0 0 0 
Dysgeusia 3 3 0 0 0 
Muscle spasms 3 3 0 0 0 
Rhinorhea 3 3 0 0 0 
Thrombocytopenia 2 0 2 0 0 
Blood bilirubin increased 2 0 2 0 0 
Epistaxis 2 1 1 0 0 
Malaise 2 2 0 0 0 
Fatigue 2 2 0 0 0 
Myalgia 2 2 0 0 0 
Nasopharyngitis 2 2 0 0 0 
Decreased appetite 2 2 0 0 0 
Ejection fraction decreased 1 0 0 1 * 0 
Neutrophil count decreased 1 0 0 1 0 
ALT increased 1 0 1 0 0 
Hemoglobin decreased 1 0 1 0 0 
Blood ALP increased 1 0 1 0 0 
Anal fistula 1 0 1 0 0 
Hemorrhagic gastric ulcer 1 0 1 0 0 
Vomiting 1 0 1 0 0 
Cystitis 1 0 1 0 0 
Anemia 1 0 1 0 0 
Table 3 Pharmacokinetic parameters of T-DM1, total trastuzumab, free DM1, and pertuzumab 
Analyte 
Cmax 
(μg/mL) 
AUClast 
(μg･
day/mL) 
AUCinf 
(μg･day/mL) 
t1/2 
(days) 
Vss 
(mL/kg) 
CL 
(mL/day/kg) 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
T-DM1 65.0 8.78 275 84.7 282 85.0 3.73 0.990 71.8 11.4 14.1 5.19 
TTmab 72.0 17.4 434 197 479 233 6.06 2.12 70.7 17.8 9.72 5.83 
Analyte 
Cmax 
(ng/mL) 
AUClast 
(ng･
day/mL) 
AUCinf 
(ng･day/mL) 
t1/2 
(days) 
Vss 
(mL/kg) 
CL 
(mL/day/kg) 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
free DM1 3.75 0.794 6.37 3.05 10.9 4.95 2.97 1.51 - - 
Analyte 
Cmax 
(μg/mL) 
AUClast 
(μg･
day/mL) 
AUCinf 
(μg･day/mL) 
t1/2 
(days) 
Vss 
(L) 
CL 
(L/day) 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Pertuzumab 301 28.9 2760 524 3970 1270 14.1 5.45 4.09 0.733 0.235 0.0929 
T-DM1, trastuzumab-DM1; TTmab, total trastuzumab; Cmax, maximum serum concentration; AUClast, area under the serum concentration-time curve from 
time zero to the last measurable concentration; AUCinf, area under the serum concentration-time curve from time zero extrapolated to infinity; t1/2, terminal 
half-life; Vss, volume of distributionat steady state; CL, total clearance; SD, standard deviation. 
Figure 1 
Comparison of PK parameters for serum T-DM1 in Japanese patients between JO22591 12 (T-DM1 3.6 
mg/kg, N=5) and JO22992 (T-DM1 3.6 mg/kg and pertuzumab, N=6): (A) comparison of maximum 
serum concentration (Cmax), (B) comparison of area under the serum concentration-time curve from 
time zero extrapolated to infinity (AUCinf). Error bars indicate standard deviation of the mean. 
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Figure 2 
Comparison of PK parameters for free T-DM1 in Japanese patients between JO22591 12 (T-DM1 3.6 
mg/kg, N=5) and JO22992 (T-DM1 3.6 mg/kg and pertuzumab, N=6): (A) comparison of maximum 
serum concentration (Cmax), (B) comparison of area under the serum concentration-time curve from 
time zero extrapolated to infinity (AUCinf). Error bars indicate standard deviation of the mean. 
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Figure 3 
Comparison of PK parameters for serum pertuzumab in Japanese patients: (A) comparison of area 
under the serum concentration-time curve from time zero extrapolated to infinity (AUCinf) for serum 
pertuzumab between JO17076 13 (pertuzumab, N=18) and JO22992 (T-DM1 3.6 mg/kg and 
pertuzumab, N=6), (B) comparison of serum pertuzumab concentration between CLEOPATRA 5-7 
(pertuzumab, trastzuaumb and docetaxel, N=4) and JO22992 (T-DM1 3.6 mg/kg and pertuzumab, 
N=6). Error bars indicate standard deviation of the mean. 
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